Abstract
Tumor vessels provide essential paths for tumor cells to escape from the primary tumor and form metastatic foci in distant organs. The vessel targeting strategy has been widely used as an important clinical cancer chemotherapeutic strategy for patients with metastatic tumors. Our review introduces the contribution of angiogenesis to tumor metastasis and summarizes the application of Food and Drug Administration (FDA)-approved vessel targeting drugs for metastatic tumors. We recommend the application and mechanisms of vascular targeting drugs for inhibiting tumor metastasis and discuss the risk and corresponding countermeasures after vessel targeting treatment.
Highlights
Tumor metastasis is the main cause of cancer-induced death
Ziv-aflibercept is composed of the extracellular domain of both VEGFR-1 and vascular endothelial growth factor receptor-2 (VEGFR-2) fused to the Fc region of IgG1, which interacts with vascular endothelial growth factor (VEGF)-B and placental growth factor (PlGF) and halts the pro-angiogenic effects of the VEGF/VEGFR signaling pathway [81,82]
The pre-metastatic niche provides a favorable environment for seeding and colonization of disseminated tumor cells in the second organ, which is essential for metastatic foci formation
Summary
Xiaobo Li 1,2,† , Yong Li 1,2,† , Weijin Lu 1,2 , Minfeng Chen 1,2 , Wencai Ye 1,2 and Dongmei Zhang 1,2, *. Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, Jinan University, Guangzhou 510632, China. Received: 25 October 2019; Accepted: 5 December 2019; Published: 10 December 2019
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call